Overview
The goal of this pilot study is to improve ovarian reserve markers in patients with premature ovarian insufficiency. The main question it aims to answer is:
- Will treatment with G-CSF allow improvement in markers of ovarian reserve?
Description
The research team hypothesize that treatment of premature ovarian insufficiency patients with G-CSF to mobilize bone marrow hematopoietic stem cells will allow for improved ovarian reserve markers including antral follicle count, anti-Mullerian hormone (AMH) levels and gonadotropin (FSH) levels. The research team anticipate these outcomes:
- Primary outcome: Decreased serum FSH and increased AMH levels and u/s measurement of increased antral follicle count (AFC)
- Secondary outcome: Improved ovarian response in IVF cycles if BAFs develop, and spontaneous or IVF pregnancy.
Eligibility
Inclusion Criteria:
- Women ages 25-40
- Woman who meet criteria for POI defined as AFC < 5, AMH < 3 pmol/L and FSH >30 IU/L. There may also be associated symptoms of the menopause such as hot flushes, night sweats, insomnia and vaginal dryness.
- Women who are not taking any other medical or fertility treatments except natural estrogen to stop hot flushes.
- Those who are provided with informed consent.
Exclusion Criteria:
- Women with age > 40
- Women with history of autoimmune disorders
- Women with a history of hematopoietic cell malignancies
- Women with sickle cell disease
- Women with any other comorbidities that would preclude infertility treatment and pregnancy such as HIV/AIDS, hepatitis B or C, breast cancer or body mass index (BMI) >40.